H Lundbeck A/S
CSE:HLUN A

Watchlist Manager
H Lundbeck A/S Logo
H Lundbeck A/S
CSE:HLUN A
Watchlist
Price: 35.3 DKK 0.28% Market Closed
Market Cap: 35.1B DKK
Section:
 

Relative Value

The Relative Value of one HLUN A stock under the Base Case scenario is hidden DKK. Compared to the current market price of 35.3 DKK, H Lundbeck A/S is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HLUN A Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

1.5
P/S
P/S
Price to Sales
1.5
vs History
36
vs Industry
61
Median 3Y
1.4
Median 5Y
1.4
Industry
2.6
Forward
1.4
More Details
9.2
P/E
P/E
Price to Earnings
9.2
vs History
47
vs Industry
38
Median 3Y
9.5
Median 5Y
9.1
Industry
21.7
More Details
10.3
P/OCF
P/OCF
Price to OCF
10.3
vs History
6
vs Industry
39
Median 3Y
7
Median 5Y
6.7
Industry
16.7
More Details
3.2
P/FCFE
P/FCFE
Price to FCFE
3.2
vs History
38
vs Industry
36
Median 3Y
2.7
Median 5Y
2.3
Industry
23.1
More Details
1.4
P/B
P/B
Price to Book Value
1.4
vs History
38
vs Industry
53
Median 3Y
1.4
Median 5Y
1.3
Industry
2.2
More Details
1.8
EV/S
EV/S
Enterprise Value to Sales
1.8
vs History
18
vs Industry
50
Median 3Y
1.5
Median 5Y
1.5
Industry
2.9
Forward
1.8
More Details
2.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.2
vs History
18
vs Industry
65
Median 3Y
1.9
Median 5Y
1.9
Industry
5.5
More Details
7.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
7.1
vs History
47
vs Industry
40
Median 3Y
7.1
Median 5Y
7
Industry
13.2
Forward
6.9
More Details
7.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
7.1
vs History
56
vs Industry
37
Median 3Y
7.6
Median 5Y
7.4
Industry
16.8
More Details
12.9
EV/OCF
EV/OCF
Enterprise Value to OCF
12.9
vs History
20
vs Industry
31
Median 3Y
6.7
Median 5Y
6
Industry
15.9
More Details
14.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
14.6
vs History
18
vs Industry
25
Median 3Y
7.5
Median 5Y
6.6
Industry
19.2
More Details
1
EV/IC
EV/IC
Enterprise Value to IC
1
vs History
54
vs Industry
60
Median 3Y
1
Median 5Y
1
Industry
1.9
More Details

Multiples Across Competitors

HLUN A Competitors Multiples
H Lundbeck A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
H Lundbeck A/S
CSE:HLUN A
35B DKK 1.5 9.2 7.1 7.1
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.1 55 36.9 39.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
496.6B USD 5.4 19.8 16.2 21
CH
Roche Holding AG
SIX:ROG
259.2B CHF 4.2 27.5 11.7 13.7
UK
AstraZeneca PLC
LSE:AZN
212B GBP 4.9 30.2 108.4 158.7
CH
Novartis AG
SIX:NOVN
208.2B CHF 4.7 18.2 11.5 14.9
US
Merck & Co Inc
NYSE:MRK
251.4B USD 3.9 13.2 9.4 11.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.3 9.3 10.8
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
143.2B USD 2.3 14.6 7.4 10.2
P/E Multiple
Earnings Growth PEG
DK
H Lundbeck A/S
CSE:HLUN A
Average P/E: 22.3
9.2
21%
0.4
US
Eli Lilly and Co
NYSE:LLY
55
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.8
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.5
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30.2
38%
0.8
CH
Novartis AG
SIX:NOVN
18.2
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
4%
3.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
H Lundbeck A/S
CSE:HLUN A
Average EV/EBITDA: 399.6
7.1
4%
1.8
US
Eli Lilly and Co
NYSE:LLY
36.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.7
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.4
10%
10.8
CH
Novartis AG
SIX:NOVN
11.5
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.4
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
H Lundbeck A/S
CSE:HLUN A
Average EV/EBIT: 1 710.9
7.1
4%
1.8
US
Eli Lilly and Co
NYSE:LLY
39.6
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.7
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.7
23%
6.9
CH
Novartis AG
SIX:NOVN
14.9
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11.2
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
8%
1.3

See Also

Summary
HLUN A intrinsic value, competitors valuation, and company profile.
DCF Valuation
HLUN A stock valuation using Discount Cash Flow valuation method.
Relative Valuation
HLUN A stock valuation using valuation multiples.
Wall Street Estimates
HLUN A price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
HLUN A stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 304,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.